Search

Your search for "silo" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Strategic Appointment of Dr. Atul Mahableshwarkar

June 11, 2024

Cybin (NYSE American: CYBN) (Cboe CA: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options. The company today announced its appointment of Dr. Atul R. Mahableshwarkar M.D., DLFAPA, as its senior vice president, clinical development. Dr. Mahableshwarkar will lead the development of the CYB003 […]

InvestorNewsBreaks

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Closes on $2M Registered Direct Offering, Provides Update on SP-26 Ketamine Implant Therapeutic

June 7, 2024

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has closed on a previously announced registered direct offering. According to the announcement, the offering was comprised of 917,432 shares of common stock (or common stock equivalents in lieu thereof) offered at a […]

InvestorNewsBreaks

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters Registered Direct Offering Estimated to Reach $2M

June 5, 2024

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has entered into definitive agreements for the purchase and sale of common stock. Specifically, the agreements are for a registered direct offering of 917,432 shares of common stock for $2.18 per share. In […]

InvestorNewsBreaks

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Pre-IND Submission for Proprietary Treatment for PTSD, Anxiety

June 4, 2024

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has submitted a pre-Investigational New Drug (“pre-IND”) briefing package and meeting request to the U.S. Food and Drug Administration (“FDA”). The submission is for Silo Pharma’s intranasal prophylactic treatment for post-traumatic stress disorder […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation at Interdisciplinary Conference on Psychedelic Research 2024

May 29, 2024

Cybin (NYSE American: CYBN) (Cboe CA: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options. The company today announced that its Chief Medical Officer Amir Inamdar, MBBS, DNB (Psych), MFPM and Director, Clinical Development Ellen James, Ph.D. will participate at the Interdisciplinary Conference on […]

InvestorNewsBreaks

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Shares ‘Significant Development’ in Depression Study Showing Potential to Extend Remission Period, Prevent Relapse

May 21, 2024

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, is reporting on results from a study that has identified a potential new drug formulation that could extend the remission period and prevent relapse in individuals dealing with depression. According to the announcement, […]

News Articles

Bebuzee Inc. (BBUZ) Looks to Challenge the Status Quo in the US and European Tech Ecosystems with the Launch of the Bebuzee Super App

May 15, 2024

Today, the common practice for companies in the American digital landscape is to create multiple applications and websites that offer customers only a fraction of the functionalities found in the super apps dominating the Asian tech ecosystem. The distributed nature of these functionalities across different platforms has long meant that services such as communication, entertainment, […]

InvestorNewsBreaks

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Participation in FDA Event Exploring Emerging Therapeutic Interest in Ketamine

May 14, 2024

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced its planned attendance at a hybrid public meeting on June 27, 2024. The meeting will be hosted by the U.S. Food and Drug Administration (“FDA”) in partnership with the […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO Slated to Present at Upcoming Alliance Global Partners Healthcare Company Showcase

May 14, 2024

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, will be participating in an upcoming virtual Alliance Global Partners Healthcare Company Showcase. The event is scheduled for May 21, 2024. According to the announcement, Cybin CEO Doug Drysdale will […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Issues Corporate Update, Eyes Runway for Upcoming Clinical Milestones

May 6, 2024

Cybin (NYSE American: CYBN) (Cboe CA: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options. The company has provided a corporate update highlighting recent clinical accomplishments and key upcoming catalysts across its development pipeline. “With the prevalence and burden of mental health conditions at […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation at the 27th Annual Milken Institute Global Conference

April 25, 2024

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, is announcing its participation at the 27th Annual Milken Institute Global Conference, set to take place May 5-8, 2024, at the Beverly Hilton in Los Angeles. According to the announcement, Doug Drysdale, Cybin CEO, will appear […]

InvestorNewsBreaks

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Update on Plan of Arrangement with Exopharm Limited

April 24, 2024

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that shareholders of Exopharm Limited ACN 163 765 991 approved a previously announced plan of arrangement between Exopharm Limited and Tryp (the “parties”). The announcement confirmed […]

InvestorNewsBreaks

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Shares Positive Results for PTSD Treatment

April 23, 2024

Silo Pharma (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company today announced positive data in the final validation report from the recent pharmacokinetic (“PK”) study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (“PTSD”). […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Research Published in “Journal of Medicinal Chemistry”

April 18, 2024

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, is reporting that its research has been published in a prestigious biweekly, peer-reviewed publication. Titled “Synthesis and Structure-Activity Relationships of 2,5-dimethoxy-4-substituted phenethylamines and the discovery of CYB210010: A potent, orally […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Receives Notice of Patent Grant for CYB003 Breakthrough MDD Therapy Program

April 16, 2024

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, has received notification that the United States Patent and Trademark Office has granted a patent in support of its CYB003 program in Major Depressive Disorder (“MDD”). The patent covers claims […]

InvestorNewsBreaks

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Plans for Exclusive Licensing of Novel Therapeutic for Alzheimer’s Disease

April 10, 2024

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, is exercising its option to license Alzheimer’s disease (“AD”) therapeutic SPC-14 from Columbia University. The option was outlined in a research and option agreement between Silo Pharma and the university in 2021. According […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Present at Bloom Burton & Co. Healthcare Conference

April 10, 2024

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, announced that its CEO Doug Drysdale will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference. The event is slated to take place April 16-17 in Toronto, Ontario. […]

InvestorNewsBreaks

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Exercises Option for Exclusive License Agreement for SPC-15

March 20, 2024

Silo Pharma (NASDAQ: SILO) is a developmental-stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company today announced that it has exercised its option to license SPC-15, a prophylactic treatment for stress-induced affective disorders including anxiety and PTSD, from Columbia University, pursuant to a sponsored […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Upcoming Public Ventures Discovery Day

March 18, 2024

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, will be presenting at this week’s Public Ventures Discovery Day. The event is scheduled for March 19, 2024, in Dallas. During the event, Cybin CEO Doug Drysdale will participate in […]

InvestorNewsBreaks

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent Application for Groundbreaking Ketamine Implant Therapeutic

March 18, 2024

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced its filing of a provisional patent application titled ‘Methods and Combinations for Managing Pain’ with the United States Patent and Trademark Office (“USPTO”). The patent application includes protection for Silo […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Initiates Phase 2 Study of CYB004 for Generalized Anxiety Disorder

March 15, 2024

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is reporting the initiation of a Phase 2 proof-of-concept study of CYB004, its proprietary deuterated dimethyltryptamine (“DMT”) molecule in development for the treatment of generalized anxiety disorder (“GAD”). The randomized, […]

InvestorNewsBreaks

InvestorNewsBreaks — Laredo Oil Inc. (LRDC) Reports That Texakoma Is Exercising Option to Drill Valley County Wells

March 14, 2024

Laredo Oil (OTC: LRDC), an oil exploration and production company, announced that Texakoma Exploration and Production LLC (“Texakoma”) has exercised its option to drill the next eight wells under its agreement with Laredo Oil’s wholly-owned subsidiary, Lustre Oil Company LLC, and Erehwon Oil & Gas, LLC. The agreement also includes participation in the development of […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports on Meeting with FDA to Review End of Phase 2 Study, Proposed Phase 3 Program

March 14, 2024

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, is reporting on its end-of-phase-2 meeting with the U.S. Food and Drug Administration (“FDA”). The meeting was regarding CYB003, the company’s deuterated psilocybin analog for the adjunctive treatment of major […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Executives Share CYB003 Program Update During Webcast

March 13, 2024

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, hosted a conference call and webcast this morning at 8:30 a.m. ET. According to the announcement, the company provided an update on CYB003, its proprietary deuterated psilocybin analog being developed […]

InvestorNewsBreaks

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Shareholders Approve Arrangement Agreement at Annual General and Special Meeting

March 13, 2024

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, announced that company shareholders approved an announced arrangement involving the company and Exopharm Limited CAN 163 765 991. Tryp securityholders approved the arrangement during the company’s annual […]

InvestorNewsBreaks

InvestorNewsBreaks — Laredo Oil Inc. (LRDC) Subsidiary Reaches Agreement to Settle Mineral Rights Litigation

March 11, 2024

Laredo Oil (OTC: LRDC), an oil exploration and production company, through its wholly owned subsidiary Lustre Oil Company LLC, has announced an agreement to settle litigation. According to the announcement, the company has entered “a mutually agreeable settlement agreement between Lustre, Erehwon Oil & Gas LLC and A&S Minerals Development Company (‘ASMD’) LLC.” The agreement, which […]

InvestorNewsBreaks

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Completes Successful Dose-Ranging Study in Advancement of SPC-15

February 28, 2024

Silo Pharma (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company today announced positive results from its non-GLP small animal dose-ranging study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (“PTSD”). The purpose of the study […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Upcoming TD Cowen Health Care Conference

February 27, 2024

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be spotlighted at next month’s 44th annual TD Cowen Health Care Conference. The three-day event is scheduled for March 4–6, 2024, in Boston. During the conference, Cybin CEO Doug Drysdale […]

InvestorNewsBreaks

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Validation of Delivery System for SP-26

February 14, 2024

Silo Pharma (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company today provided a positive update on SP-26, its novel time-released, dose-controlled formulation of ketamine initially targeted for fibromyalgia. According to the announcement, a pre-clinical research study is underway […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Q3 Results, Recent Business Highlights

February 14, 2024

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic treatment options, today announced unaudited financial results for its third quarter ended Dec. 31, 2023, and recent business highlights. “During the past three months, we have continued to make exciting progress […]

InvestorNewsBreaks

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Interim Order from BC Supreme Court, Plans Meeting of Securityholders

February 9, 2024

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has obtained an interim order of the Supreme Court of British Columbia in connection with the proposed arrangement between Tryp and Exopharm Limited ACN 163 765 991. […]

InvestorNewsBreaks

InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Compounds Receive USPTO Notice of Allowances

February 8, 2024

Mydecine Innovations (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE: 0NF0), a leading biotechnology company dedicated to transforming mental-health and addiction treatment, has been issued two Notice of Allowances by the United States Patent and Trademark Office (“USPTO”). The allowances are for compounds from the company’s MYCO-005 and MYCO-006 families. MYCO-005 is a novel compound for […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures Two New JP Patents, Further Broadening IP Portfolio in Key Markets

February 7, 2024

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company has announced that the Japan Patent (“JP”) Office has granted patents 2023-500532 and 2023-533436, which are expected to provide exclusivity until at least 2040 and 2041, respectively. The […]

InvestorNewsBreaks

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Prioritize Clinical Pipeline Targeting Mental Health, Chronic Pain and Neurology

February 1, 2024

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced updates for its strategic 2024 focus for its clinical pipeline. According to the announcement, the company is advancing a diversified portfolio of four drugs targeting three health areas: mental health, […]

InvestorNewsBreaks

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Exopharm Limited Secure Approval from ASX for ‘Pivotal’ Two-Cent Waiver

January 26, 2024

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, announced that it has been granted a pivotal two-cent waiver by the Australian Securities Exchange (“ASX”). According to the announcement, the waiver was also granted to Exopharm […]

InvestorNewsBreaks

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Highlights Positive Results of Alzheimer’s Study

January 24, 2024

Silo Pharma (NASDAQ: SILO), a biopharmaceutical company developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that its Alzheimer’s disease therapeutic SPC-14 showed positive efficacy in small animals. Data from the study conducted at Columbia University in collaboration with Silo Pharma showed that SPC-14 was effective against LH stress […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives FDA Clearance to Begin CYB004 Study for Generalized Anxiety Disorder

January 23, 2024

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has received approval from the U.S. Food and Drug Administration (“FDA”) for its investigational new drug (“IND”) application for its proprietary deuterated dimethyltryptamine (“DMT”) molecule: CYB004. The clearance means that Cybin can move […]

InvestorNewsBreaks

InvestorNewsBreaks — Laredo Oil Inc. (LRDC) Subsidiary Enters Drilling Agreement for Montana Wells

January 22, 2024

Laredo Oil (OTC: LRDC), an oil exploration and production company, and its wholly owned subsidiary, Hell Creek Crude LLC (“HCC”), has entered into a participation agreement with Erehwon Oil & Gas LLC and various accredited investors. According to the announcement, the agreement initially provides more than $2 million in cash, which will be used to fund the […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Promising Topline Data from Phase 1 CYB004 and SPL028 Studies

January 8, 2024

Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, today announced positive safety, pharmacokinetic (“PK”) and pharmacodynamic (“PD”) data from its phase 1 studies of CYB004 (“IV” administration) and SPL028 (“IV” and “IM” administration) in healthy volunteers. CYB004 and SPL028 […]

InvestorNewsBreaks

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) TRP-8803 Clinical Trial Reaches ‘Significant Milestone’

January 8, 2024

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has received approval from Australia’s Human Research Ethics Committee (“HREC”) to commence a groundbreaking phase 1 clinical trial of TRP-8803 (IV-infused psilocin) in healthy human volunteers. According […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).